ARCTIC: Liquid Biomarkers in Prostate Cancer
This study is for men with metastatic castration-resistant prostate cancer. Researchers want to understand if certain genes or proteins, called "biomarkers," found in circulating tumor cells (CTCs) can predict how well patients will respond to their standard hormonal therapies. CTCs are cancer cells that break away from a tumor and enter the bloodstream. By studying these biomarkers, the goal is to learn which patients might benefit most from specific treatments. The study will follow participants for up to three years to compare how long patients live without their cancer getting worse (progression-free survival) based on whether they have certain biomarkers.
- Study design
- This is an observational study that plans to enroll 120 men. It will follow participants throughout their standard of care treatment.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed through completion of their participation, for up to 3 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
At a glance
Conditions
Where it's being run
3 sites across 3 statesStudy leadership
- Andrew Armstrong, MD · PRINCIPAL_INVESTIGATOR · Duke University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Comparison of progression-free survival (PFS) between biomarker positive and negative participantsThrough completion of participant participation, up to 3 years
PFS which is defined as the time from date of study enrollment to radiographic or clinical progression or death. Radiographic progression will be defined by Prostate Cancer Working Group 3 (PCWG3) criteria for soft tissue and bone metastases and will not include PSA changes alone. Clinical progression will be defined as clinical deterioration requiring a change in therapy, such as a pathologic fracture or symptomatic skeletal event or pain progression in the absence of imaging progression.